https://www.biopharmawatch.com/news/A/agilent-announces-cash-dividend-25-5-cents BiopharmaWatch en 2026-09-16T22:59:00.000Z CORRECTING and REPLACING Agilent Announces Cash Dividend of 25.5 Cents per Share https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-inducement-grants-cmo BiopharmaWatch en 2026-09-16T21:33:00.000Z AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/LGVN/longeveron-elpis-ii-trial-results-hlhs BiopharmaWatch en 2026-09-16T21:27:00.000Z Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS) https://www.biopharmawatch.com/news/HALO/halozyme-proposed-offering-convertible-senior-notes BiopharmaWatch en 2026-09-16T20:30:00.000Z Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033 https://www.biopharmawatch.com/news/PNTG/pennant-acquires-mainplace-senior-living-orange-california BiopharmaWatch en 2026-09-16T20:30:00.000Z Pennant Acquires Real Estate of Mainplace Senior Living in Orange, California https://www.biopharmawatch.com/news/BRVE/braveheart-bio-participate-stifel-cardiometabolic-forum BiopharmaWatch en 2026-09-16T20:30:00.000Z Braveheart Bio to Participate in Stifel Cardiometabolic Forum https://www.biopharmawatch.com/news/A/agilent-announces-quarterly-dividend-25-5-cents BiopharmaWatch en 2026-09-16T20:15:00.000Z Agilent Announces Cash Dividend of 25.5 Cents per Share https://www.biopharmawatch.com/news/MDAI/spectral-ai-deepview-system-burn-indication-srbc BiopharmaWatch en 2026-09-16T20:15:00.000Z Spectral AI Showcases DeepView® System for Burn Indication and KOL Research at Southern Regional Burn Conference https://www.biopharmawatch.com/news/BIIB/biogen-third-quarter-2026-financial-results BiopharmaWatch en 2026-09-16T20:06:00.000Z Biogen to Report Third Quarter 2026 Financial Results October 28, 2026 https://www.biopharmawatch.com/news/GOSS/gossamer-bio-appoints-greg-ciongoli-board BiopharmaWatch en 2026-09-16T20:01:00.000Z Gossamer Bio Appoints Greg Ciongoli to Board of Directors https://www.biopharmawatch.com/news/AVLN/avalyn-appoints-robert-meyer-board-directors BiopharmaWatch en 2026-09-16T20:01:00.000Z Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors https://www.biopharmawatch.com/news/IPHA/innate-sobi-partnership-effective-closing-conditions BiopharmaWatch en 2026-09-16T20:00:00.000Z Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions https://www.biopharmawatch.com/news/MOH/molina-donates-trauma-informed-care-iowa-youth BiopharmaWatch en 2026-09-16T18:00:00.000Z The MolinaCares Accord and Molina Healthcare of Iowa Donate $50,000 to Expand Trauma-Informed Care for Iowa Youth https://www.biopharmawatch.com/news/TMO/thermo-fisher-junior-innovators-challenge-2026-finalists BiopharmaWatch en 2026-09-16T16:03:00.000Z Thirty Inspiring Middle School Scientists and Engineers Named Finalists in the 2026 Thermo Fisher Scientific Junior Innovators Challenge https://www.biopharmawatch.com/news/WAT/everlywell-partnership-waters-hpv-screening-tool BiopharmaWatch en 2026-09-16T14:00:00.000Z Everlywell Announces a Partnership with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients https://www.biopharmawatch.com/news/DNA/ginkgo-datapoints-partnership-tunelab-ai-drug-discovery BiopharmaWatch en 2026-09-16T13:52:00.000Z Ginkgo Datapoints Announces Partnership with TuneLab to Close the Gap between AI Models and Lab Data https://www.biopharmawatch.com/news/NXGL/nexgel-announces-investor-update-call-date BiopharmaWatch en 2026-09-16T13:29:00.000Z NEXGEL Announces Date for Investor Update Call https://www.biopharmawatch.com/news/LNAI/lunai-bioworks-ai-chemical-risk-screening BiopharmaWatch en 2026-09-16T13:25:00.000Z Lunai Bioworks (Nasdaq: LNAI) Demonstrates AI Chemical-Risk Screening for Generative AI https://www.biopharmawatch.com/news/IBO/impact-biomedical-merger-zoar-ltd-registration-filing BiopharmaWatch en 2026-09-16T13:20:00.000Z Impact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley’s Limited) https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-dr-carmen-guerra-advisory-board BiopharmaWatch en 2026-09-16T13:15:00.000Z Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board https://www.biopharmawatch.com/news/SYK/stryker-foot-ankle-innovation-aofas-2026 BiopharmaWatch en 2026-09-16T13:06:00.000Z Stryker showcases Foot & Ankle innovation at AOFAS 2026 with Prophecy® Surgical Planning for Incompass™ and Hoffmann® LRF smartHEX™ https://www.biopharmawatch.com/news/BIO/bio-rad-fireside-chat-bernstein-forum BiopharmaWatch en 2026-09-16T13:00:00.000Z Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum https://www.biopharmawatch.com/news/MLSS/milestone-scientific-compuflo-development-partner BiopharmaWatch en 2026-09-16T13:00:00.000Z Milestone Scientific Announces Pain and Spine Specialists and Dr. Sudhir Rao as CompuFlo® Development Partner and Advisor https://www.biopharmawatch.com/news/NRXS/neuraxis-medical-coverage-policy-expansion BiopharmaWatch en 2026-09-16T13:00:00.000Z NeurAxis Announces Medical Coverage Policy Milestone, Expanding Access to Over 18 million additional Covered Lives https://www.biopharmawatch.com/news/CVS/cvs-health-wear-your-heart-bandage-art-contest BiopharmaWatch en 2026-09-16T13:00:00.000Z CVS Health Launches National "Wear Your HeART" Bandage Art Contest https://www.biopharmawatch.com/news/NTHI/neonc-insider-buying-fda-focus BiopharmaWatch en 2026-09-16T12:46:00.000Z NeOnc’s $629K Insider Buying Spree Follows Breakthrough Data and Now All Eyes Turn to the FDA https://www.biopharmawatch.com/news/AUNA/auna-host-2026-investor-day-october-22 BiopharmaWatch en 2026-09-16T12:45:00.000Z Auna to Host 2026 Investor Day on October 22, 2026 https://www.biopharmawatch.com/news/CODX/co-diagnostics-readygo-ebola-testing-collaboration BiopharmaWatch en 2026-09-16T12:45:00.000Z Co-Diagnostics and ReadyGo Collaborate to Evaluate Blood-Based Molecular Testing at the Point of Need, Starting with Ebola https://www.biopharmawatch.com/news/GILD/gilead-accelerates-global-access-lenacapavir-hiv-prevention BiopharmaWatch en 2026-09-16T12:30:00.000Z Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention https://www.biopharmawatch.com/news/CAH/cardinal-health-lawsuits-dismissed-pharmacy-customers BiopharmaWatch en 2026-09-16T12:30:00.000Z Cardinal Health Loses Multiple "Product Return" Lawsuits Against Pharmacy Customers and Pays Attorneys' Fees to Settle Sanctions Motion for Frivolous Litigation https://www.biopharmawatch.com/news/CUPR/cuprina-holdings-public-offering-pricing BiopharmaWatch en 2026-09-16T12:30:00.000Z Cuprina Holdings (Cayman) Limited Announces Pricing of $4.97 million Public Offering https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-avim-therapy-hrx-live-2026 BiopharmaWatch en 2026-09-16T12:30:00.000Z Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026 https://www.biopharmawatch.com/news/AMIX/autonomix-medical-appoints-sandra-kalter-board BiopharmaWatch en 2026-09-16T12:30:00.000Z Autonomix Medical Appoints Former Medtronic Chief Regulatory Counsel Sandra Cohen Kalter to Board of Directors https://www.biopharmawatch.com/news/OGEN/oragenics-cmo-present-ipac-rs-2026-nasal-innovation-forum BiopharmaWatch en 2026-09-16T12:30:00.000Z Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum https://www.biopharmawatch.com/news/RVMD/propanc-prp-emt-reversal-ras-inhibitors BiopharmaWatch en 2026-09-16T12:30:00.000Z Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc. https://www.biopharmawatch.com/news/EQ/equillium-participate-stifel-2026-immunology-forum BiopharmaWatch en 2026-09-16T12:30:00.000Z Equillium to Participate in Stifel’s 2026 Virtual Immunology and Inflammation Forum https://www.biopharmawatch.com/news/OPTH/optimi-health-phase-3-mdma-ptsd-trial BiopharmaWatch en 2026-09-16T12:25:00.000Z Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-first-patient-phase-2-trial BiopharmaWatch en 2026-09-16T12:15:00.000Z MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial https://www.biopharmawatch.com/news/VIVS/vivosim-namkind-drug-toxicity-data-eurotox-2026 BiopharmaWatch en 2026-09-16T12:05:00.000Z VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs https://www.biopharmawatch.com/news/DGX/medicare-lab-payment-cuts-survey-results BiopharmaWatch en 2026-09-16T12:03:00.000Z Nine in 10 Voters Express Concern That Medicare Lab Payment Cuts Will Harm Patient Access to Diagnostic Lab Testing, Finds National Survey from Quest Diagnostics https://www.biopharmawatch.com/news/NTHI/neonc-executives-invest-stock-after-positive-phase-2a-results BiopharmaWatch en 2026-09-16T12:00:39.000Z NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Phase 2a Results https://www.biopharmawatch.com/news/HYPR/medtechwomen-hyperfine-ceo-maria-sainz-award BiopharmaWatch en 2026-09-16T12:00:00.000Z MedtechWOMEN Names Hyperfine CEO Maria Sainz Winner of 2026 Ferolyn Powell Leadership Award https://www.biopharmawatch.com/news/TWST/twist-bioscience-lilly-tunelab-antibody-drug-discovery BiopharmaWatch en 2026-09-16T12:00:00.000Z Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery https://www.biopharmawatch.com/news/ADGM/adagio-medical-first-patient-ide-study-vclas-ultra BiopharmaWatch en 2026-09-16T12:00:00.000Z Adagio Medical Highlights First Patient Treated in IDE Study Evaluating Next-Generation vCLAS™ Ultra System for Ventricular Tachycardia at Banner – University Medical Center Phoenix https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-regains-nasdaq-compliance BiopharmaWatch en 2026-09-16T12:00:00.000Z Alzamend Neuro Regains Compliance with Nasdaq Listing Standards https://www.biopharmawatch.com/news/XCUR/exicure-nasdaq-extension-compliance-stockholders-equity BiopharmaWatch en 2026-09-16T12:00:00.000Z Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders’ Equity Requirement https://www.biopharmawatch.com/news/ODTX/odyssey-therapeutics-stifel-2026-forum BiopharmaWatch en 2026-09-16T12:00:00.000Z Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum https://www.biopharmawatch.com/news/MYGN/myriad-genetics-appoints-vishal-sikri-evp-commercial BiopharmaWatch en 2026-09-16T12:00:00.000Z Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial https://www.biopharmawatch.com/news/STXS/stereotaxis-ai-automation-hrx-2026 BiopharmaWatch en 2026-09-16T11:59:00.000Z Stereotaxis Emerging Digital, AI and Automation Capabilities to be Featured at Heart Rhythm Society’s HRX 2026 https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-art27-13-weight-loss-semaglutide BiopharmaWatch en 2026-09-16T11:30:00.000Z Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity https://www.biopharmawatch.com/news/CNSY/cerenome-appoints-samantha-fowlkes-commercial-sales BiopharmaWatch en 2026-09-16T11:30:00.000Z Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-uf-health-zevaskyn-activation BiopharmaWatch en 2026-09-16T11:30:00.000Z Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN® https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-warrant-exercise-7-million BiopharmaWatch en 2026-09-16T11:27:00.000Z Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds https://www.biopharmawatch.com/news/ACB/aurora-cannabis-business-update-acquisition-safari-flower BiopharmaWatch en 2026-09-16T11:05:00.000Z Aurora Cannabis Provides Business Update; Accretive Acquisition of Safari Flower Company and Leading European Performance Expected to Fuel International Growth in the Fiscal Second Quarter 2027 and Beyond https://www.biopharmawatch.com/news/XBIO/xenetic-santersus-share-exchange-agreement-net-therapeutics BiopharmaWatch en 2026-09-16T11:00:00.000Z Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics https://www.biopharmawatch.com/news/ALKS/alkermes-appoints-anne-whitaker-board-directors BiopharmaWatch en 2026-09-16T11:00:00.000Z Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors https://www.biopharmawatch.com/news/IDXX/idexx-acquires-covetai-veterinary-workflow-intelligence BiopharmaWatch en 2026-09-16T11:00:00.000Z IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence https://www.biopharmawatch.com/news/INSM/insmed-global-day-of-good-2026 BiopharmaWatch en 2026-09-16T11:00:00.000Z Insmed Expands Community Impact During Fifth Annual Global Day of Good https://www.biopharmawatch.com/news/KLRA/kailera-therapeutics-september-investor-conferences BiopharmaWatch en 2026-09-16T11:00:00.000Z Kailera Therapeutics to Participate in September Investor Conferences https://www.biopharmawatch.com/news/NRXS/neuraxis-participate-lytham-partners-fall-2026-investor-conference BiopharmaWatch en 2026-09-16T11:00:00.000Z NeurAxis to Participate in the Lytham Partners Fall 2026 Investor Conference https://www.biopharmawatch.com/news/FATE/fate-therapeutics-acr-convergence-2026-presentations BiopharmaWatch en 2026-09-16T11:00:00.000Z Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026 https://www.biopharmawatch.com/news/VTRS/viatris-approval-wakix-japan-narcolepsy-osas BiopharmaWatch en 2026-09-16T10:59:00.000Z Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome https://www.biopharmawatch.com/news/CMPS/compass-pathways-td-cowen-summit-participation-2026 BiopharmaWatch en 2026-09-16T10:30:00.000Z Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026 https://www.biopharmawatch.com/news/MDT/medtronic-fda-clearance-ligasure-ras-maryland-instrument BiopharmaWatch en 2026-09-16T10:30:00.000Z Medtronic announces FDA clearance for LigaSure™ RAS Maryland instrument on the Hugo™ RAS system https://www.biopharmawatch.com/blog/phase-2-3-readouts-week-of-2026-09-14 BiopharmaWatch en 2026-09-16T07:15:26.171Z Upcoming Phase 3 Readouts: Key Insights and Analysis https://www.biopharmawatch.com/news/BIIB/leqembi-pen-approval-japan-alzheimers-treatment BiopharmaWatch en 2026-09-16T06:00:31.000Z LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease https://www.biopharmawatch.com/news/BBNX/beta-bionics-public-offering-pricing BiopharmaWatch en 2026-09-16T03:56:00.000Z Beta Bionics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants https://www.biopharmawatch.com/news/OILS/nextleaf-leadership-transition-sam-kassem-ceo BiopharmaWatch en 2026-09-15T23:50:00.000Z Nextleaf Announces Leadership Transition and Strategic Review; Sam Kassem Appointed Interim CEO https://www.biopharmawatch.com/news/CARL/carlsmed-patent-infringement-lawsuit-degen-medical BiopharmaWatch en 2026-09-15T23:00:00.000Z Carlsmed, Inc. Files Patent Infringement Lawsuit against DeGen Medical https://www.biopharmawatch.com/news/RPRX/royalty-pharma-donation-blood-cancer-united-tap BiopharmaWatch en 2026-09-15T20:36:51.000Z Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program https://www.biopharmawatch.com/news/NEOG/neogen-first-quarter-earnings-release-date BiopharmaWatch en 2026-09-15T20:30:00.000Z Neogen Announces First-Quarter Earnings Release Date https://www.biopharmawatch.com/news/EHC/encompass-health-rehabilitation-hospital-lower-providence BiopharmaWatch en 2026-09-15T20:30:00.000Z Encompass Health Rehabilitation Hospital of Lower Providence now open in Pennsylvania https://www.biopharmawatch.com/news/RPRX/blood-cancer-united-royalty-pharma-donation BiopharmaWatch en 2026-09-15T20:30:00.000Z Blood Cancer United Announces $7.5 Million Gift From Royalty Pharma to Expand Therapy Acceleration Program https://www.biopharmawatch.com/news/CODX/co-diagnostics-press-conference-sept-16-2026 BiopharmaWatch en 2026-09-15T20:15:00.000Z Co-Diagnostics to Hold Press Conference https://www.biopharmawatch.com/news/CRON/cronos-host-2026-investor-day-kingsville-ontario BiopharmaWatch en 2026-09-15T20:15:00.000Z Cronos to Host 2026 Investor Day at its Cronos GrowCo Facility in Kingsville, Ontario https://www.biopharmawatch.com/news/BBNX/beta-bionics-public-offering-125-million BiopharmaWatch en 2026-09-15T20:13:00.000Z Beta Bionics Announces Proposed Public Offering of $125.0 Million of Common Stock https://www.biopharmawatch.com/news/TPST/tempest-exclusive-option-license-cd7-targeted-car-t BiopharmaWatch en 2026-09-15T20:05:11.000Z Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-regulatory-clinical-appointments BiopharmaWatch en 2026-09-15T20:05:00.000Z Jasper Therapeutics Announces Key Regulatory and Clinical Appointments https://www.biopharmawatch.com/news/NRXP/nrxp-fda-update-preservative-free-ketamine BiopharmaWatch en 2026-09-15T19:11:00.000Z NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine https://www.biopharmawatch.com/news/HIMS/hims-and-hers-class-action-lawsuit BiopharmaWatch en 2026-09-15T19:08:00.000Z Shareholders who lost money in shares of acquired Hims & Hers Health, Inc. (NYSE: HIMS) should contact Wolf Haldenstein Immediately https://www.biopharmawatch.com/news/PZZA/papa-johns-shareholder-lawsuit-wolf-haldenstein BiopharmaWatch en 2026-09-15T18:54:00.000Z Shareholders who lost money in shares of acquired Papa John's International, Inc. (NASDAQ: PZZA) should contact Wolf Haldenstein Immediately https://www.biopharmawatch.com/news/SNN/smith-nephew-tender-offer-2030-bonds BiopharmaWatch en 2026-09-15T18:00:00.000Z Smith & Nephew Plc Announces Pricing of Cash Tender Offer for 2030 Bonds https://www.biopharmawatch.com/news/PRCT/lawsuit-notice-procept-biorobotics-investors BiopharmaWatch en 2026-09-15T17:15:00.000Z LAWSUIT NOTICE: NASDAQ: PRCT Investors who lost money with PROCEPT BioRobotics Corporation shares should contact the Shareholders Foundation https://www.biopharmawatch.com/news/FEED/envue-medical-nasdaq-listing-update BiopharmaWatch en 2026-09-15T16:45:00.000Z ENvue Medical Provides Nasdaq Listing Update https://www.biopharmawatch.com/news/MEDS/datameds-acquires-helomics-ai-cancer-diagnostics BiopharmaWatch en 2026-09-15T16:05:00.000Z DataMEDS, AI. Acquires Helomics AI Cancer Diagnostics Lab and Precision Oncology CRO Businesses from Axe Compute https://www.biopharmawatch.com/news/GILD/gilead-paho-partnership-lenacapavir-hiv-prevention BiopharmaWatch en 2026-09-15T15:10:00.000Z Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean https://www.biopharmawatch.com/news/MEDP/supporting-complex-phase-i-studies-integrated-imaging BiopharmaWatch en 2026-09-15T14:15:39.000Z Supporting Complex Phase I Studies Through Integrated Imaging and Specialized Assessments https://www.biopharmawatch.com/news/NTHI/neonc-technologies-investor-focus-nthi BiopharmaWatch en 2026-09-15T13:53:00.000Z Investor Determination to Beat Cancer Puts NeOnc’s Novel Therapies and Patented Platform in Focus https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-09-14 BiopharmaWatch en 2026-09-15T13:43:25.882Z Biotech Catalysts to Watch: Key Events and Insights for Investors https://www.biopharmawatch.com/news/HSTM/healthstream-private-placement-40-million BiopharmaWatch en 2026-09-15T13:25:00.000Z HealthStream Completes $40 Million Private Placement of Its Common Stock https://www.biopharmawatch.com/news/HSCS/heartsciences-fiscal-q1-2027-results-business-update BiopharmaWatch en 2026-09-15T13:25:00.000Z HeartSciences Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/GTBP/gt-biopharma-gtb-5550-multiple-myeloma-indication BiopharmaWatch en 2026-09-15T13:15:00.000Z GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma https://www.biopharmawatch.com/news/BTMD/solfarcos-expands-us-market-partnerships BiopharmaWatch en 2026-09-15T13:00:00.000Z Biotech Innovator Solfarcos Brings Capabilities Behind K18 Development to New Markets https://www.biopharmawatch.com/news/LFMD/att-free-access-virtual-healthcare-lifemd BiopharmaWatch en 2026-09-15T13:00:00.000Z AT&T Becomes the First and Only Carrier to Offer Free Access to Virtual Healthcare Powered by LifeMD https://www.biopharmawatch.com/news/FEMY/femasys-ob-gyn-expansion-femaseed-minnesota BiopharmaWatch en 2026-09-15T13:00:00.000Z Femasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women’s Care https://www.biopharmawatch.com/news/CLNN/clene-announces-4-million-registered-direct-offering BiopharmaWatch en 2026-09-15T13:00:00.000Z Clene Announces $4 Million Registered Direct Offering https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-positive-preclinical-data-erna-201 BiopharmaWatch en 2026-09-15T12:42:00.000Z Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing https://www.biopharmawatch.com/news/CVM/cel-sci-keynote-multikine-6th-world-congress BiopharmaWatch en 2026-09-15T12:37:00.000Z CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology https://www.biopharmawatch.com/news/HCA/hca-healthcare-acquisition-college-health-care-professions BiopharmaWatch en 2026-09-15T12:30:00.000Z HCA Healthcare Completes Acquisition of the College of Health Care Professions https://www.biopharmawatch.com/news/ABBV/abbvie-birdies-for-brain-health-pga-tour BiopharmaWatch en 2026-09-15T12:30:00.000Z AbbVie Named Official Pharmaceutical Sponsor of the PGA TOUR and 2026 Presidents Cup, Launches Birdies for Brain Health Campaign https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-milestone-payment-vivasure-haemonetics BiopharmaWatch en 2026-09-15T12:30:00.000Z Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics https://www.biopharmawatch.com/news/PYPD/polypid-participation-fall-investor-conferences BiopharmaWatch en 2026-09-15T12:30:00.000Z PolyPid Announces Participation in Upcoming Fall Investor Conferences https://www.biopharmawatch.com/news/AQB/aquabounty-engages-colliers-exclusive-agent-ohio-property BiopharmaWatch en 2026-09-15T12:15:00.000Z AquaBounty Announces Engagement of Colliers as Exclusive Agent for its Ohio Property https://www.biopharmawatch.com/news/HYPR/hyperfine-completes-enrollment-contrast-pmr-study BiopharmaWatch en 2026-09-15T12:15:00.000Z Hyperfine Announces Completion of Enrollment in the Contrast PMR Study to Support the Submission to Expand Indications for Use of the Swoop® System with Contrast Agents https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-stock-purchases-ceo-board-member BiopharmaWatch en 2026-09-15T12:15:00.000Z MAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO https://www.biopharmawatch.com/news/ADIA/adia-med-2026-clinical-study-osteoarthritis-treatment BiopharmaWatch en 2026-09-15T12:00:00.000Z Adia Med Submits Fifth 2026 Clinical Study to IRB: Osteoarthritis Protocol for One-Time Systemic Treatment https://www.biopharmawatch.com/news/EXE/extendicare-september-2026-dividend-announcement BiopharmaWatch en 2026-09-15T12:00:00.000Z Extendicare Announces September 2026 Dividend of C$0.0441 per Share https://www.biopharmawatch.com/news/TMO/mayo-clinic-thermo-fisher-precure-launch BiopharmaWatch en 2026-09-15T12:00:00.000Z Mayo Clinic and Thermo Fisher Scientific launch Precure, LLC to identify signs of disease before symptoms appear https://www.biopharmawatch.com/news/ARDT/ardent-health-hospitals-us-news-best-hospitals-2026-2027 BiopharmaWatch en 2026-09-15T12:00:00.000Z Ardent Health Hospitals Earn Recognition in U.S. News & World Report’s 2026-2027 Best Hospitals Rankings https://www.biopharmawatch.com/news/GEHC/ge-healthcare-careintellect-operations-launch BiopharmaWatch en 2026-09-15T12:00:00.000Z GE HealthCare Announces CareIntellect for Operations, Helping Health Systems Optimize Resources and Expand Access to Care https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-us-patent-allowance-mescaline-derivatives BiopharmaWatch en 2026-09-15T12:00:00.000Z Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series https://www.biopharmawatch.com/news/COYA/coya-therapeutics-phase-2-3-alstars-trial-100th-participant BiopharmaWatch en 2026-09-15T12:00:00.000Z Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS https://www.biopharmawatch.com/news/NUVB/nuvation-bio-ibtrozi-efficacy-ros1-nsclc-wclc-2026 BiopharmaWatch en 2026-09-15T12:00:00.000Z Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer https://www.biopharmawatch.com/news/BDMD/baird-medical-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-15T12:00:00.000Z Baird Medical to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-appoints-susan-kozauer-cmo BiopharmaWatch en 2026-09-15T12:00:00.000Z LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical Officer https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-japanese-patent-stenoparib-diagnostic BiopharmaWatch en 2026-09-15T12:00:00.000Z Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development https://www.biopharmawatch.com/news/LEGN/legend-biotech-appoints-ingrid-zhang-ceo BiopharmaWatch en 2026-09-15T12:00:00.000Z Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer https://www.biopharmawatch.com/news/MDT/sonus-medtronic-ai-maternal-health-monitoring BiopharmaWatch en 2026-09-15T12:00:00.000Z Sonus Microsystems and Medtronic Partner to Advance AI-Powered Maternal Health Monitoring https://www.biopharmawatch.com/news/COGT/cogent-biosciences-fda-acceptance-bezuclastinib-advsm BiopharmaWatch en 2026-09-15T12:00:00.000Z Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) https://www.biopharmawatch.com/news/LFWD/lifeward-rewalk-exoskeleton-study-improvements BiopharmaWatch en 2026-09-15T12:00:00.000Z Peer-Reviewed Study of Lifeward’s ReWalk® Exoskeleton Reports Significant Improvements in Daily Activity Performance, Satisfaction, and Pain https://www.biopharmawatch.com/news/SCYX/scynexis-appoints-todd-minga-svp-research-development BiopharmaWatch en 2026-09-15T12:00:00.000Z SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development https://www.biopharmawatch.com/news/RHEL/rhelion-filament-health-usc-agreement-pex010 BiopharmaWatch en 2026-09-15T11:59:00.000Z Rhelion Life Sciences Wholly Owned Subsidiary Filament Health Signs Supply and Licensing Agreement with the University of Southern California for PEX010 in a Trial for Psilocybin-Assisted Mindfulness Therapy https://www.biopharmawatch.com/news/OSTX/os-therapies-uk-mhra-eu-ema-cmaa-filing BiopharmaWatch en 2026-09-15T11:46:00.000Z OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing https://www.biopharmawatch.com/news/EBS/emergent-ribbon-cutting-canton-manufacturing-facility BiopharmaWatch en 2026-09-15T11:45:00.000Z Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility https://www.biopharmawatch.com/news/VRTX/vertex-lindsey-vonn-journavx-awareness BiopharmaWatch en 2026-09-15T11:30:00.000Z Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-aro-dimer-pa-clinical-data BiopharmaWatch en 2026-09-15T11:30:00.000Z Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia https://www.biopharmawatch.com/news/BIVI/biovie-address-lc-trial-bezisterim-long-covid-results BiopharmaWatch en 2026-09-15T11:30:00.000Z BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID https://www.biopharmawatch.com/news/TLT/theralase-glp-toxicology-analysis-rutherrin BiopharmaWatch en 2026-09-15T11:00:00.000Z Theralase(R) Commences GLP Toxicology Analysis of Rutherrin(R) https://www.biopharmawatch.com/news/BHST/bioharvest-vinia-daily-chews-launch BiopharmaWatch en 2026-09-15T11:00:00.000Z BioHarvest Advances Botanical Synthesis Leadership as VINIA Daily Chews Unlock More Value from Its First Consumer Product https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-preciise-btn-clinical-study-enrollment BiopharmaWatch en 2026-09-15T11:00:00.000Z Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-fda-alignment-rp-a501-danon-disease BiopharmaWatch en 2026-09-15T11:00:00.000Z Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-pre-nda-meeting-axpaxli-wet-amd BiopharmaWatch en 2026-09-15T11:00:00.000Z Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD https://www.biopharmawatch.com/news/CNTB/connect-biopharma-positive-data-rademikibart-asthma BiopharmaWatch en 2026-09-15T11:00:00.000Z Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation https://www.biopharmawatch.com/news/MSLE/satellos-present-world-muscle-society-congress BiopharmaWatch en 2026-09-15T11:00:00.000Z Satellos to Present at the 31st Annual Congress of the World Muscle Society https://www.biopharmawatch.com/news/BLSM/blossomhill-therapeutics-bh-30643-phase-1-2-trial-results BiopharmaWatch en 2026-09-15T11:00:00.000Z BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer https://www.biopharmawatch.com/news/COSM/cosmos-health-target-pharma-agreements-growth BiopharmaWatch en 2026-09-15T10:30:00.000Z Cosmos Health Adds 5.2 Million Units in New Five-Year Agreements with Target Pharma; Orderbook Surges Past 32.7 Million Units, Up 31% Since June https://www.biopharmawatch.com/news/TELO/telo-genomics-telemrd-multiple-myeloma-relapse BiopharmaWatch en 2026-09-15T10:30:00.000Z Telo Genomics Announces Clinical Research Results Evidencing Utility of Its Telomere Analysis Platform in Predicting Multiple Myeloma Relapse https://www.biopharmawatch.com/news/CMPS/compass-pathways-change-tune-trd-launch BiopharmaWatch en 2026-09-15T10:30:00.000Z Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 2026 https://www.biopharmawatch.com/news/VERA/veras-trutakna-origins-3-trial-results BiopharmaWatch en 2026-09-15T10:30:00.000Z Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy https://www.biopharmawatch.com/news/UTMD/utmd-announces-self-tender-for-20-percent-of-shares BiopharmaWatch en 2026-09-15T10:00:00.000Z UTMD Announces Self-Tender for 20% of Its Shares https://www.biopharmawatch.com/news/HEAL/holy-crap-foods-chfa-now-toronto-exhibit BiopharmaWatch en 2026-09-15T10:00:00.000Z Holy Crap Foods to Exhibit at CHFA NOW Toronto, Debuting New Protein SKUs and Interactive AI Photo Experience https://www.biopharmawatch.com/news/SMMT/harmoni-data-wclc-2026-ivonescimab BiopharmaWatch en 2026-09-15T10:00:00.000Z Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients https://www.biopharmawatch.com/news/PFSA/profusa-nasdaq-compliance-determination BiopharmaWatch en 2026-09-15T10:00:00.000Z Profusa, Inc. Receives Nasdaq Compliance Determination https://www.biopharmawatch.com/news/RVVTF/revive-therapeutics-expand-bucillamine-ip-portfolio BiopharmaWatch en 2026-09-15T09:35:00.000Z Revive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical Countermeasures and Rare Diseases https://www.biopharmawatch.com/news/NNVC/clinical-trial-nv-387-ebola-drug-drc BiopharmaWatch en 2026-09-15T09:25:00.000Z Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48% Crude Fatality Rate, Says NanoViricides https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-advances-crps-program-painweek-2026 BiopharmaWatch en 2026-09-15T09:15:00.000Z Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation https://www.biopharmawatch.com/news/JAGX/jaguar-health-reverse-stock-split BiopharmaWatch en 2026-09-15T09:00:00.000Z Jaguar Health, Inc. Announces Reverse Stock Split https://www.biopharmawatch.com/news/IBO/impact-biomedical-reverse-stock-split-merger-zoar BiopharmaWatch en 2026-09-15T01:26:00.000Z CORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited) https://www.biopharmawatch.com/news/LLY/lilly-easd-2026-cardiometabolic-health-data BiopharmaWatch en 2026-09-15T00:00:00.000Z Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health Pivotal results from TRIUMPH-2 showed retatrutide, an investigational triple hormone receptor agonist, delivered substantial weight loss and A1C... https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-acquisition-actio-biosciences BiopharmaWatch en 2026-09-15T00:00:00.000Z Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") today announced the successful completion of its acquisition of privately-held...